Anvisa acted correctly, but needs to launch the vaccine soon, say former agency directors



[ad_1]

  • André Shalders – @andreshalders
  • BBC News Brazil in Brasilia

Caption,

In Brazil, the CoronaVac studies are carried out jointly by Sinovac and Instituto Butantan

The National Health Surveillance Agency (Anvisa) was correct in determining the discontinuation of clinical trials of the CoronaVac vaccine after the death of a study participant. Now, however, the municipality must quickly publish the return of studies with the immunizer developed by the Chinese pharmaceutical company Sinovac.

The opinion is a consensus between two former Anvisa presidents consulted by BBC News Brazil: Doctors Gonzalo Vecina and William Dib.

The tests with the CoronaVac vaccine were interrupted this Monday (11/11), after the communication that one of the participants in the clinical tests was found dead in São Paulo, at the end of October. The volunteer, however, would have committed suicide, according to a police report from the São Paulo Civil Police. Death, therefore, would have nothing to do with the vaccine.

Heard separately by BBC News Brazil, the two former Anvisa presidents said the agency needs to publish the return of the studies soon, especially if there are already reports from forensic doctors confirming that the death of the 32-year-old volunteer was due to suicide. .

[ad_2]